Skip to main content
. 2016 Jun 22;5(6):509–516. doi: 10.1002/cpdd.272

Table 4.

Adverse Events Occurring in at Least 2 Patients by Treatment (Safety Population)

Adverse Event, n (%) Cabotegravir 150 mg (n = 40) Cabotegravir Placebo (n = 39) Moxifloxacin 400 mg (n = 36)
Any adverse event 13 (33) 16 (41) 12 (33)
Dermatitis contact 6 (15) 9 (23) 2 (6)
Headache 1 (3) 2 (5) 2 (6)
Nausea 0 0 2 (6)
Alanine aminotransferase increased 1 (3) 1 (3) 0
Blood creatine phosphokinase increased 0 1 (3) 1 (3)